Beximco Pharmaceuticals (BXP) Competitors GBX 44.61 -1.89 (-4.07%) As of 11:43 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock BXP vs. BGSC, GROW, PINE, PRSR, SAGA, DX, ARR, SOHO, MGP, and ADVTShould you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include BMO Global Smaller Companies (BGSC), Molten Ventures (GROW), Pinewood Technologies Group (PINE), Prs Reit (PRSR), Saga (SAGA), DX (Group) (DX), Aurora Investment Trust (ARR), Triple Point Social Housing REIT (SOHO), Medica Group (MGP), and AdvancedAdvT (ADVT). These companies are all part of the "trading" industry. Beximco Pharmaceuticals vs. Its Competitors BMO Global Smaller Companies Molten Ventures Pinewood Technologies Group Prs Reit Saga DX (Group) Aurora Investment Trust Triple Point Social Housing REIT Medica Group AdvancedAdvT Beximco Pharmaceuticals (LON:BXP) and BMO Global Smaller Companies (LON:BGSC) are both small-cap trading companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Do institutionals and insiders hold more shares of BXP or BGSC? 1.2% of Beximco Pharmaceuticals shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is BXP or BGSC more profitable? Beximco Pharmaceuticals has a net margin of 13.71% compared to BMO Global Smaller Companies' net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 13.12% beat BMO Global Smaller Companies' return on equity.Company Net Margins Return on Equity Return on Assets Beximco Pharmaceuticals13.71% 13.12% 6.97% BMO Global Smaller Companies N/A N/A N/A Is BXP or BGSC a better dividend stock? Beximco Pharmaceuticals pays an annual dividend of GBX 3.97 per share and has a dividend yield of 8.9%. BMO Global Smaller Companies pays an annual dividend of GBX 0.02 per share. Beximco Pharmaceuticals pays out 27.8% of its earnings in the form of a dividend. BMO Global Smaller Companies pays out 0.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Which has higher earnings & valuation, BXP or BGSC? Beximco Pharmaceuticals has higher revenue and earnings than BMO Global Smaller Companies. BMO Global Smaller Companies is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeximco Pharmaceuticals£46.34B0.00£970.84B£14.253.13BMO Global Smaller Companies£303.85M0.00N/A£50.70N/A Does the media refer more to BXP or BGSC? In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.75 beat BMO Global Smaller Companies' score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Beximco Pharmaceuticals Positive BMO Global Smaller Companies Neutral SummaryBeximco Pharmaceuticals beats BMO Global Smaller Companies on 9 of the 11 factors compared between the two stocks. Get Beximco Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BXP vs. The Competition Export to ExcelMetricBeximco PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£198.99M£1.61B£5.66B£2.57BDividend Yield5.63%2.94%5.75%5.32%P/E Ratio3.1372.1576.225,390.72Price / Sales0.001,683.49559.2398,506.30Price / CashN/A10.3737.6027.92Price / Book0.0011.3712.378.03Net Income£970.84B£20.70B£3.29B£5.89B7 Day Performance-5.32%0.17%1.07%15.32%1 Month Performance-10.79%0.19%3.59%2.69%1 Year Performance86.01%5.10%60.72%156.67% Beximco Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BXPBeximco PharmaceuticalsN/AGBX 44.61-4.1%N/A+89.1%£198.99M£46.34B3.135,500High Trading VolumeBGSCBMO Global Smaller CompaniesN/AN/AN/AN/A£769.56M£303.85M2.77N/AGROWMolten Ventures2.8886 of 5 starsGBX 364.40+3.5%GBX 580+59.2%-9.6%£645.75M£31.70M-91,100.0020Positive NewsPINEPinewood Technologies Group3.246 of 5 starsGBX 549flatGBX 590+7.5%+23.8%£628.49M£3.86B879.815,334News CoverageEarnings ReportAnalyst ForecastInsider TradePRSRPrs ReitN/AGBX 111.95+1.0%N/A+7.7%£614.86M£116.05M559.732High Trading VolumeSAGASaga1.3184 of 5 starsGBX 216.50+0.2%N/A+134.2%£311.66M£588.30M-184.413,682Trending NewsEarnings ReportAnalyst ForecastDXDX (Group)N/AN/AN/AN/A£306.77M£471.20M1,185.0020ARRAurora Investment TrustN/AGBX 247-0.4%N/A-0.8%£276.22M-£9.71M-1,836.43N/ANews CoverageEarnings ReportSOHOTriple Point Social Housing REITN/AGBX 68.66-1.3%N/A+6.6%£270.17M-£24.90M-742.3110Positive NewsMGPMedica GroupN/AN/AN/AN/A£259.85M£76.98M3,516.671,212ADVTAdvancedAdvTN/AGBX 188-1.1%N/A+49.0%£256.48M£43.27M2,350.00209 Related Companies and Tools Related Companies BMO Global Smaller Companies Competitors Molten Ventures Competitors Pinewood Technologies Group Competitors Prs Reit Competitors Saga Competitors DX (Group) Competitors Aurora Investment Trust Competitors Triple Point Social Housing REIT Competitors Medica Group Competitors AdvancedAdvT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BXP) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beximco Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Beximco Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
